OBJECTIVES: The aim of this study was to evaluate the association of fibroblast growth factor (FGF)-23 with clinical and laboratory findings, the prognostic value of @entity11648 , and the relationship between @entity7774 -converting  enzyme inhibitor (ACEi) therapy, @entity11648 levels, and outcomes in @entity1 with chronic @entity712 ( @entity712 ). BACKGROUND: @entity11648 is a bone-derived hormone regulating mineral metabolism. Higher @entity11648 levels are associated with an increased risk of @entity65 or @entity712 development. Mechanisms leading to increased @entity11648 and its prognostic value have not been thoroughly studied in @entity712 . METHODS: @entity11648 was measured in 369 @entity1 (mean age 59    11 years, 84% male) with systolic @entity712 . @entity1 were followed for adverse events (e.g., @entity204 , urgent heart transplantation, ventricular assist device implantation). RESULTS: @entity997 severity, @entity740 ( @entity740 ), alkaline phosphatase concentrations, inferior vena cava dilation, and absence of ACEi therapy were independently associated with @entity11648 . @entity11648 was independently associated with outcomes in @entity1 without @entity740 (hazard ratio [HR]: 1.43, 95% confidence interval [CI]: 1.14 to 1.78), but not in @entity740 @entity1 (HR: 1.12, 95% CI: 0.87 to 1.45). In @entity1 without @entity740 and with @entity11648 in the highest tertile, ACEi therapy was associated with a lower risk of adverse events (HR: 0.42, 95% CI: 0.21 to 0.81), whereas no association was seen in the remaining @entity1 (HR: 1.18, 95% CI: 0.52 to 2.70). CONCLUSIONS: In systolic @entity712 , elevated @entity11648 is an independent predictor of adverse events, particularly in @entity1 with preserved renal function. The association of @entity11648 with adverse events likely reflects early alterations of renal hemodynamics and renin-angiotensin system activation. Increased @entity11648 may identify a subset of @entity712 @entity1 benefiting from ACEi therapy.

Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['HF', 'systolic heart failure'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['angiotensin'] @entity11648 :: ('8074', 'Gene') :: ['FGF-23'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease'] @entity997 :: ('MESH:D014262', 'Disease') :: ['Tricuspid regurgitation'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality']
@entity712 :: (MESH:D006333,Disease) :: ['Chronic Systolic  Heart  Failure']
